Oxidative Stress in Cancer-Prone Genetic Diseases in Pediatric Age: The Role of Mitochondrial Dysfunction

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Perrone, Serafina ^a   Lotti, Federica ^a   Geronzi, Ursula ^a   Guidoni, Elisa ^a   Longini, Mariangela ^a,b   Buonocore, Giuseppe ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIA; OXIDATIVE STRESS;

ATAXIA TELANGIECTASIA; CANCER PREDISPOSITION; GENETIC DISEASE; GENETIC DISORDERS; MITOCHONDRIAL DYSFUNCTION; MOLECULAR MECHANISM; PROGEROID SYNDROME; THERAPEUTIC TARGETS;

DISEASES;

ANTIOXIDANT; ASCORBIC ACID; REACTIVE OXYGEN METABOLITE; TRACE ELEMENT; ANTINEOPLASTIC AGENT;

ARTICLE; ATAXIA TELANGIECTASIA; BECKWITH WIEDEMANN SYNDROME; BLOOM SYNDROME; CANCER GENETICS; CARCINOGENESIS; COSTELLO SYNDROME; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOUBLE STRANDED DNA BREAK; DOWN SYNDROME; FANCONI ANEMIA; FATTY ACID SYNTHESIS; GENETIC DISORDER; GENOME IMPRINTING; GENOMIC INSTABILITY; HUMAN; LIFESPAN; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRADER WILLI SYNDROME; QUALITY OF LIFE; SINGLE STRANDED DNA BREAK; WERNER SYNDROME; AGE; ANIMAL; BECKWITH-WIEDEMANN SYNDROME; CELL TRANSFORMATION; COMPLICATION; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MITOCHONDRIAL DISEASES; MITOCHONDRION; NEOPLASMS; PRADER-WILLI SYNDROME; RISK FACTOR;

AGE FACTORS; ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; BECKWITH-WIEDEMANN SYNDROME; CELL TRANSFORMATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEOPLASMS; OXIDATIVE STRESS; PRADER-WILLI SYNDROME; RISK FACTORS;

EID: 84973125246     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/4782426     Document Type: Article

References (101)

1. B. Halliwell, "Reactive oxygen species in living systems: source, biochemistry, and role in human disease,"TheAmerican Journal of Medicine, vol. 91, no. 3, pp. S14-S22, 1991.
2. B. Halliwell, "Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?"TheLancet, vol. 344, no.8924, pp. 721-724, 1994.
3. K. Brieger, S. Schiavone, F. J. Miller Jr., and K.-H. Krause, "Reactive oxygen species: fromhealth to disease," SwissMedical Weekly, vol. 142, Article IDw13659, 2012.
4. M. Gutowski and S. Kowalczyk, "A study of free radical chemistry: their role and pathophysiological significance," Acta Biochimica Polonica, vol. 60, no. 1, pp. 1-16, 2013.
5. B. Halliwell, "Oxidative stress and cancer: have we moved forward?" Biochemical Journal, vol. 401, no. 1, pp. 1-11, 2007.
6. G. Waris and H. Ahsan, "Reactive oxygen species: role in the development of cancer and various chronic conditions," Journal of Carcinogenesis, vol. 5, article 14, 2006.
7. D.Harman, "Aging: a theory based on free radical and radiation chemistry," Journal of Gerontology, vol. 11, no. 3, pp. 298-300, 1956.
8. M. D. Evans, M. Dizdaroglu, and M. S. Cooke, "Oxidative DNA damage and disease: induction, repair and significance," Mutation Research/Reviews in Mutation Research, vol. 567, no. 1, pp. 1-61, 2004.
9. M. Valko, M. Izakovic, M. Mazur, C. J. Rhodes, and J. Telser, "Role of oxygen radicals inDNA damage and cancer incidence," Molecular and Cellular Biochemistry, vol. 266, no. 1-2, pp. 37-56, 2004.
10. M. Valko, C. J. Rhodes, J. Moncol, M. Izakovic, and M. Mazur, "Free radicals, metals and antioxidants in oxidative stressinduced cancer," Chemico-Biological Interactions, vol. 160, no. 1, pp. 1-40, 2006.
11. A. Abdal Dayem, H.-Y. Choi, J.-H. Kim, and S.-G. Cho, "Role of oxidative stress in stem, cancer, and cancer stem cells," Cancers, vol. 2, no. 2, pp. 859-884, 2010.
12. F. Michor, Y. Iwasa, B. Vogelstein, C. Lengauer, and M. A. Nowak, "Can chromosomal instability initiate tumorigenesis?" Seminars in Cancer Biology, vol. 15, no. 1, pp. 43-49, 2005.
13. N. P. Degtyareva, L. Chen, P. Mieczkowski, T. D. Petes, and P. W. Doetsch, "Chronic oxidative DNA damage due to DNA repair defects causes chromosomal instability in Saccharomyces cerevisiae," Molecular and Cellular Biology, vol. 28, no. 17, pp. 5432-5445, 2008.
14. P. A. Cerutti and B. F. Trump, "Inflammation and oxidative stress in carcinogenesis," Cancer Cells, vol. 3, no. 1, pp. 1-7, 1991.
15. L. R. Ferguson, "Chronic inflammation and mutagenesis," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 690, no. 1-2, pp. 3-11, 2010.
16. J. Miquel and J. E. Fleming, "A two-step hypothesis on the mechanisms of in vitro cell aging: cell differentiation followed by intrinsic mitochondrial mutagenesis," Experimental Gerontology, vol. 19, no. 1, pp. 31-36, 1984.
17. C. Kenyon, "The plasticity of aging: insights from long-lived mutants," Cell, vol. 120, no. 4, pp. 449-460, 2005.
18. E. Dufour and N.-G. Larsson, "Understanding aging: revealing order out of chaos," Biochimica et Biophysica Acta (BBA)- Bioenergetics, vol. 1658, no. 1-2, pp. 122-132, 2004.
19. D. C. Wallace, "A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine," Annual Review of Genetics, vol. 39, pp. 359-407, 2005.
20. R. S. Balaban, S. Nemoto, and T. Finkel, "Mitochondria, oxidants, and aging," Cell, vol. 120, no. 4, pp. 483-495, 2005.
21. G. Pagano, A. Aiello Talamanca, G. Castello et al., "Oxidative stress and mitochondrial dysfunction across broad-ranging pathologies: toward mitochondria-targeted clinical strategies," OxidativeMedicine and Cellular Longevity, vol. 2014,Article ID 541230, 27 pages, 2014.
22. F. V. Pallardó, A. Lloret, M. Lebel et al., "Mitochondrial dysfunction in some oxidative stress-related genetic diseases: ataxia-Telangiectasia, Down Syndrome, Fanconi Anaemia and Werner Syndrome," Biogerontology, vol. 11, no. 4, pp. 401-419, 2010.
23. G. Barrera, F. Gentile, S. Pizzimenti et al., "Mitochondrial dysfunction in cancer and neurodegenerative diseases: spotlight on fatty acid oxidation and lipoperoxidation products," Antioxidants, vol. 5, no. 1, article 7, 2016.
24. P. R. Pandey, W. Liu, F. Xing, K. Fukuda, and K.Watabe, "Anticancer drugs targeting fatty acid synthase (FAS)," Recent Patents on Anti-Cancer Drug Discovery, vol. 7, no. 2, pp. 185-197, 2012.
25. D. R. Wise and C. B. Thompson, "Glutamine addiction: a new therapeutic target in cancer," Trends in Biochemical Sciences, vol. 35, no. 8, pp. 427-433, 2010.
26. O.Warburg, "On the origin of cancer cells," Science, vol. 123, no. 3191, pp. 309-314, 1956.
27. M. L. Boland, A. H. Chourasia, and K. F. Macleod, "Mitochondrial dysfunction in cancer," Frontiers in Oncology, vol. 3, article 292, 2013.
28. J. Liu, "The effects and mechanisms of mitochondrial nutrient -lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview," Neurochemical Research, vol. 33, no. 1, pp. 194-203, 2008.
29. C. Musicco, V. Capelli, V. Pesce et al., "Accumulation of overoxidized Peroxiredoxin III in aged rat liver mitochondria," Biochimica et Biophysica Acta (BBA)-Bioenergetics, vol. 1787, no. 7, pp. 890-896, 2009.
30. A. Abadi, J. D. Crane, D. Ogborn et al., "Supplementation with -lipoic acid, CoQ10, and vitamin E augments running performance and mitochondrial function in female mice," PLoS ONE, vol. 8, no. 4,Article ID e60722, 2013.
31. O. Firuzi, R. Miri, M. Tavakkoli, and L. Saso, "Antioxidant therapy: current status and future prospects," CurrentMedicinal Chemistry, vol. 18, no. 25, pp. 3871-3888, 2011.
32. H. Moon, "Chemopreventive effects of alpha lipoic acid on obesity-related cancers," Annals of Nutrition and Metabolism, vol. 68, no. 2, pp. 137-144, 2016.
33. L. Tiano and J. Busciglio, "Mitochondrial dysfunction and Down's syndrome: is there a role for coenzymeQ10?" BioFactors, vol. 37, no. 5, pp. 386-392, 2011.
34. S. A. Mortensen, "Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and endpoints of 'Q-symbio'-a multinational trial," BioFactors, vol. 18, no. 1-4, pp. 79-89, 2003.
35. L. Tiano, L. Padella, P. Carnevali et al., "Coenzyme Q10 and oxidative imbalance in Down syndrome: biochemical and clinical aspects," BioFactors, vol. 32, no. 1-4, pp. 161-167, 2008.
36. R. R. Ramsay, "The role of the carnitine system in peroxisomal fatty acid oxidation," American Journal of the Medical Sciences, vol. 318, no. 1, pp. 28-35, 1999.
37. M. E. T. I. Boerrigter, C. Franceschi, E. Arrigoni-Martelli, J. Y. Wei, and J. Vijg, "The effect of L-carnitine and acetyl-Lcarnitine on the disappearance of DNA single-strand breaks in human peripheral blood lymphocytes," Carcinogenesis, vol. 14, no. 10, pp. 2131-2136, 1993.
38. A.Vanella, A. Russo, R.Acquaviva et al., "L-Propionyl-carnitine as superoxide scavenger, antioxidant, andDNAcleavage protector," Cell Biology and Toxicology, vol. 16, no. 2, pp. 99-104, 2000.
39. E. Boder, "Ataxia-telangiectasia: an overview," Kroc Foundation Series, vol. 19, pp. 1-63, 1985.
40. M. S.Meyn, "Ataxia-telangiectasia, cancer and the pathology of the ATM gene," Clinical Genetics, vol. 55, pp. 289-304, 1999.
41. R. Reliene and R. H. Schiestl, "Experimental antioxidant therapy in ataxia-telangiectasia," ClinicalMedicine: Oncology, vol. 2, pp. 431-436, 2008.
42. Y. Su and M. Swift, "Mortality rates among carriers of ataxiatelangiectasia mutant alleles," Annals of Internal Medicine, vol. 133, no. 10, pp. 770-778, 2000.
43. Y. Shiloh, "ATM and related protein kinases: safeguarding genome integrity," Nature Reviews Cancer, vol. 3, no. 3, pp. 155-168, 2003.
44. M. F. Lavin, G. Birrell, P. Chen, S. Kozlov, S. Scott, and N. Gueven, "ATM signaling and genomic stability in response to DNA damage," Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 569, no. 1-2, pp. 123-132, 2005.
45. M. Stumm, S. Neubauer, S. Keindorff, R.-D. Wegner, P. Wieacker, and R. Sauer, "High frequency of spontaneous translocations revealed by FISH in cells from patients with the cancer-prone syndromes ataxia-telangiectasia and Nijmegen breakage syndrome," Cytogenetics and Cell Genetics, vol. 92, no. 3-4, pp. 186-191, 2001.
46. J. Reichenbach, R. Schubert, D. Schindler, K.Müller, H. Böhles, and S. Zielen, "Elevated oxidative stress in patients with ataxiatelangiectasia," Antioxidants & Redox Signaling, vol. 4, no. 3, pp. 465-469, 2002.
47. Y. Aksoy, O. Sanal, A.Metin et al., "Antioxidant enzymes in red blood cells and lymphocytes of ataxia-telangiectasia patients," Turkish Journal of Pediatrics, vol. 46, no. 3, pp. 204-207, 2004.
48. S. Ziv, O. Brenner, N. Amariglio et al., "Impaired genomic stability and increased oxidative stress exacerbate different features of Ataxia-telangiectasia," Human Molecular Genetics, vol. 14, no. 19, pp. 2929-2943, 2005.
49. L. B. Ludwig, V. H. Valiati, R. P. Palazzo et al., "Chromosome instability and oxidative stress markers in patients with ataxia telangiectasia and their parents," BioMed Research International, vol. 2013, Article ID 762048, 7 pages, 2013.
50. S. Ditch and T. T. Paull, "The ATM protein kinase and cellular redox signaling: beyond the DNA damage response," Trends in Biochemical Sciences, vol. 37, no. 1, pp. 15-22, 2012.
51. M. Ambrose and R. A. Gatti, "Pathogenesis of ataxiatelangiectasia: the next generation of ATM functions," Blood, vol. 121, no. 20, pp. 4036-4045, 2013.
52. C. Cosentino, D. Grieco, and V. Costanzo, "ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair," The EMBO Journal, vol. 30, no. 3, pp. 546-555, 2011.
53. M. Ambrose, J. V. Goldstine, and R. A. Gatti, "Intrinsic mitochondrial dysfunction in ATM-deficient lymphoblastoid cells," Human Molecular Genetics, vol. 16, no. 18, pp. 2154-2164, 2007.
54. A. D. D'Souza, I. A. Parish, D. S. Krause, S. M. Kaech, and G. S. Shadel, "Reducing mitochondrial ROS improves disease-related pathology in a mousemodel of ataxia-telangiectasia,"Molecular Therapy, vol. 21, no. 1, pp. 42-48, 2013.
55. A. Berni, R.Meschini, S. Filippi, F. Palitti, A. De Amicis, and L. Chessa, "l-carnitine enhances resistance to oxidative stress by reducing DNA damage in Ataxia telangiectasia cells," Mutation Research/Genetic Toxicology and Environmental Mutagenesis, vol. 650, no. 2, pp. 165-174, 2008.
56. A. D. Auerbach, "Fanconi anemia and its diagnosis," Mutation Research, vol. 668, no. 1-2, pp. 4-10, 2009.
57. B. P. Alter and G. Kupfer, "Fanconi anemia," in Gene Reviews, R. A. Pagon, T. D. Bird, C. R. Dolan et al., Eds., University of Washington, Seattle,Wash, USA, 2013.
58. G.-L. Moldovan and A. D. D'Andrea, "How the fanconi anemia pathway guards the genome," Annual Review of Genetics, vol. 43, pp. 223-249, 2009.
59. H. Kim and A. D. D'Andrea, "Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway," Genes and Development, vol. 26, no. 13, pp. 1393-1408, 2012.
60. X. Su and J. Huang, "The Fanconi anemia pathway and DNA interstrand cross-link repair," Protein and Cell, vol. 2, no. 9, pp. 704-711, 2011.
61. C. J. Marsit, M. Liu, H. H. Nelson, M. Posner, M. Suzuki, and K. T. Kelsey, "Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival," Oncogene, vol. 23, no. 4, pp. 1000-1004, 2004.
62. I. Nordenson, "Effect of superoxide dismutase and catalase on spontaneously occurring chromosome breaks in patients with Fanconi's anemia," Hereditas, vol. 86, no. 2, pp. 147-150, 1977.
63. G. Pagano, A. Talamanca, G. Castello, F. V. Pallardò, A. Zatterale, and P.Degan, "Oxidative stress in Fanconi anaemia: from cells and molecules towards prospects in clinical management," Biological Chemistry, vol. 393, no. 1-2, pp. 11-21, 2012.
64. W. Du, Z. Adam, R. Rani, X. Zhang, and Q. Pang, "Oxidative stress in fanconi anemia hematopoiesis and disease progression," Antioxidants and Redox Signaling, vol. 10, no. 11, pp. 1909-1921, 2008.
65. W. Du, R. Rani, J. Sipple et al., "The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters," Blood, vol. 119, no. 18, pp. 4142-4151, 2012.
66. U. Kumari, W. Ya Jun, B. Huat Bay, and A. Lyakhovich, "Evidence of mitochondrial dysfunction and impaired ROS detoxifyingmachinery in Fanconi Anemia cells," Oncogene, vol. 33, no. 2, pp. 165-172, 2014.
67. S. S. Mukhopadhyay, K. S. Leung, M. J. Hicks, P. J. Hastings, H. Youssoufian, and S. E. Plon, "Defective mitochondrial peroxiredoxin-3 results in sensitivity to oxidative stress in Fanconi anemia," Journal of Cell Biology, vol. 175, no. 2, pp. 225-235, 2006.
68. F. Ponte, R. Sousa, A. P. Fernandes et al., "Improvement of genetic stability in lymphocytes from Fanconi anemia patients through the combined effect of -lipoic acid and Nacetylcysteine," Orphanet Journal of Rare Diseases, vol. 7, article 28, 2012.
69. Y.-T. Huang, J.-J. Hwang, P.-P. Lee et al., "Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor," British Journal of Pharmacology, vol. 128, no. 5, pp. 999-1010, 1999.
70. N. Rayamajhi, S.-K. Kim, H. Go et al., "Quercetin induces mitochondrial biogenesis through activation of HO-1 in HEPG2 cells," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 154279, 10 pages, 2013.
71. S. E. Antonarakis, R. Lyle, E. T. Dermitzakis, A. Reymond, and S. Deutsch, "Chromosome 21 and Down syndrome: from genomics to pathophysiology," Nature Reviews Genetics, vol. 5, no. 10, pp. 725-738, 2004.
72. L. Seewald, J. W. Taub, K. W. Maloney, and E. R. B. McCabe, "Acute leukemias in children with Down syndrome," Molecular Genetics and Metabolism, vol. 107, no. 1-2, pp. 25-30, 2012.
73. B. Lange, "The management of neoplastic disorders of haematopoeisis in children with Down's syndrome," British Journal of Haematology, vol. 110, no. 3, pp. 512-524, 2000.
74. G. T. Capone, "Down syndrome: advances in molecular biology and the neurosciences," Journal of Developmental and Behavioral Pediatrics, vol. 22, no. 1, pp. 40-59, 2001.
75. S. Perrone, M. Longini, C. V. Bellieni et al., "Early oxidative stress in amniotic fluid of pregnancies with Down syndrome," Clinical Biochemistry, vol. 40, no. 3-4, pp. 177-180, 2007.
76. I. T. Lott, "Antioxidants in Down syndrome," Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1822, no. 5, pp. 657-663, 2012.
77. M. Perluigi and D. A. Butterfield, "Oxidative stress and down syndrome: a route toward Alzheimer-like dementia," Current Gerontology and Geriatrics Research, vol. 2012, Article ID 724904, 10 pages, 2012.
78. L. Tiano, P. Carnevali, L. Padella et al., "Effect of Coenzyme Q10 in mitigating oxidative DNA damage in Down syndrome patients, a double blind randomized controlled trial," Neurobiology of Aging, vol. 32, no. 11, pp. 2103-2105, 2011.
79. L. Tiano, L. Padella, L. Santoro et al., "Prolonged coenzyme Q10 treatment in Down syndrome patients, effect on DNA oxidation," Neurobiology of Aging, vol. 33, no. 3, pp. 626.e1-626.e8, 2012.
80. T. M. Nicotera, J. Notaro, S. Notaro, J. Schumer, and A. A. Sandberg, "Elevated superoxide dismutase in Bloom's syndrome: a genetic condition of oxidative stress," Cancer Research, vol. 49, no. 19, pp. 5239-5243, 1989.
81. A. Zatterale, F. J. Kelly, P. Degan et al., "Oxidative stress biomarkers in four Bloom syndrome (BS) patients and in their parents suggest in vivo redox abnormalities in BS phenotype," Clinical Biochemistry, vol. 40, no. 15, pp. 1100-1103, 2007.
82. A. Lloret, R. Calzone, C. Dunster et al., "Different patterns of in vivo pro-oxidant states in a set of cancer-or aging-related genetic diseases," Free Radical Biology andMedicine, vol. 44, no. 4, pp. 495-503, 2008.
83. C. L. Navarro, P. Cau, and N. Lévy, "Molecular bases of progeroid syndromes," Human Molecular Genetics, vol. 15, no. 2, pp. R151-R161, 2006.
84. M. Seco-Cervera, M. Spis, J. L. Garca-Giménez et al., "Oxidative stress and antioxidant response in fibroblasts fromWerner and Atypical Werner Syndromes," Aging, vol. 6, no. 3, pp. 231-245, 2014.
85. R.Weksberg, J. Nishikawa, O. Caluseriu et al., "Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1," Human Molecular Genetics, vol. 10, no. 26, pp. 2989-3000, 2001.
86. K. A. Rauen, "HRAS and the Costello syndrome," Clinical Genetics, vol. 71, no. 2, pp. 101-108, 2007.
87. D. Yang, M.-T.Wang, Y. Tang et al., "Impairment ofmitochondrial respiration in mouse fibroblasts byoncogenic H-RASQ6IL," Cancer Biology & Therapy, vol. 9, no. 2, pp. 122-133, 2010.
88. T. Kleefstra, S. B. Wortmann, R. J. T. Rodenburg et al., "Mitochondrial dysfunction and organic aciduria in five patients carrying mutations in the Ras-MAPK pathway," European Journal of Human Genetics, vol. 19, no. 2, pp. 138-144, 2011.
89. C. Anichini, F. Lotti, A. Pietrini et al., "Antioxidant effects of potassium ascorbate with ribose in costello syndrome," Anticancer Research, vol. 33, no. 2, pp. 691-696, 2013.
90. C. Anichini, C. Lo Rizzo, M. Longini et al., "Beckwith-Wiedemann syndrome: potassium ascorbate with ribose therapy in a syndrome with high neoplastic risk," Anticancer Research, vol. 31, no. 11, pp. 3973-3976, 2011.
91. N. Hertz and R. E. Lister, "Improved survival in patients with end-stage cancer treated with coenzyme Q10 and other antioxidants: a pilot study," Journal of InternationalMedical Research, vol. 37, no. 6, pp. 1961-1971, 2009.
92. Y. Takemura, M. Satoh, H. Hamada, Y. Sekido, K. Satoh, and S. Kubota, "High dose of ascorbic acid induces cell death in mesothelioma cells," Biochemical and Biophysical Research Communications, vol. 394, no. 2, pp. 249-253, 2010.
93. H. B. Pollard, M. A. Levine, O. Eidelman, and M. Pollard, "Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer," In Vivo, vol. 24, no. 3, pp. 249-255, 2010.
94. M. J. González, G. Rosario-Pérez, A. M. Guzmàn et al., "Mitochondria, energy and cancer: the relationship with ascorbic acid," The Journal of OrthomolecularMedicine, vol. 25, no. 1, pp. 29-38, 2010.
95. C. Anichini, F. Lotti, M. Longini et al., "Antioxidant effects of potassium ascorbate with ribose therapy in a case with Prader Willi Syndrome," Disease Markers, vol. 33, no. 4, pp. 179-183, 2012.
96. P. G. Yazdi, H. Su, S. Ghimbovschi et al., "Differential gene expression reveals mitochondrial dysfunction in an imprinting center deletion mouse model of Prader-willi syndrome," Clinical and Translational Science, vol. 6, no. 5, pp. 347-355, 2013.
97. I. Nenekidis, G. T. Stathopoulos, V. Anagnostakou et al., "Atypical pulmonary carcinoid tumour in a 28-year-old nonsmoker with Prader-Willi syndrome," European Respiratory Journal, vol. 38, no. 5, pp. 1230-1233, 2011.
98. S. Rainier and A. P. Feinberg, "Genomic imprinting, DNA methylation, and cancer," Journal of the National Cancer Institute, vol. 86, no. 10, pp. 753-759, 1994.
99. H.Meng, H. Meng, Y. Cao et al., "DNA methylation, itsmediators and genome integrity," International Journal of Biological Sciences, vol. 11, no. 5, pp. 604-617, 2015.
100. E. J. Chapman and M. A. Knowles, "Necdin: a multi functional protein with potential tumor suppressor role?" Molecular Carcinogenesis, vol. 48, no. 11, pp. 975-981, 2009.
101. L. E. De Faveri, C. D. Hurst, F. M. Platt et al., "Putative tumour suppressor gene Necdin is hypermethylated and mutated in human cancer," British Journal of Cancer, vol. 108, no. 6, pp. 1368-1377, 2013.